We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Mgc Pharmaceuticals Limited | MXC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 22.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 22.00 | 22.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 10/4/2024 21:55 by sloppyjoe2 Driven your company into the ground? Failed to deliver a single one of the promises made to shareholders? Out of money and investor sentiment? Need a new flock of gullible sheep to fleece? Simples - just change your name and start over. Rinse and repeat... |
Posted at 08/11/2023 10:04 by tomboyb TIDMMXCRNS Number : 7958S MGC Pharmaceuticals Limited 08 November 2023 MGC Pharmaceuticals Ltd. Capital Consolidation and US$7.9m Placement Completed 8 November 2023 ASX, LSE: MXC MGC Pharmaceuticals Ltd (MGC Pharma, MGC or the Company), a European based pharmaceutical company specialising in the production and development of innovative medicines for unmet medical needs, is pleased to announce that following shareholder approval at a General Meeting held on 25 October 2023, the consolidation of the Company's total issued capital on a 1:1,000 basis (Consolidation) has been completed, along with the settlement of the US$7.9m share placement (Placement) as announced on 1 November 2023. Upon completion of the Consolidation and Placement, the Company's capital structure will consist of the below: Class of Securities Number of Securities Fully Paid Ordinary Shares 35,430,491 -------------------- Unlisted options exercisable at US$0.32 on or before 7 November 2028 15,500,000 -------------------- Unlisted options (various ex. price from GBP1.20 to A$13.00, April 2024-July 2026) 858,824 -------------------- Performance Rights 18,400 -------------------- Convertible Notes (Mercer Opportunities Fund) 7,306,432 -------------------- As previously announced on 1 November 2023, the Company would like to clarify that following the Consolidation and Placement, only 3,067,543 ordinary shares were be admitted to the Financial Conduct Authority's Official List and to trading on the Main Market of London Stock Exchange plc. The remaining 32,362,948 ordinary shares (post completion of the Placement) that have not being admitted to trading were issued to the Australian market and are trading on the Australian Stock Exchange. These remaining ordinary shares are anticipated to be admitted to the Financial Conduct Authority's Official List and to trading on the Main Market of London Stock Exchange plc in due course and in accordance with the applicable regulatory timeframe under the FCA Listing Rules. Voting Rights The Company has 35,430,491 ordinary shares in issue, each with one voting right. Therefore, the Company ' s total number of shares on issue and voting rights is 35,430,491. This may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA ' s Disclosure Guidance and Transparency Rules. Roby Zomer, Managing Director and CEO of MGC Pharma, commented: "I am delighted to announce that the Company has successfully concluded its full capital restructuring and refinancing, thanks to the backing of a number of strategic, high net worth investors from the United States and Europe. These individuals fully understand the Company's long-term potential and are committed to supporting its operations, execution of the business plan to maximise the MGC Pharma enterprise value and shareholder returns. As of today, our Company is now fully funded and well-positioned to proceed with the execution of its pharmaceutical work plan for 2024." - Ends- Authorised for release by the Board of Directors, for further information please contact: MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd Roby Zomer Rowan Harland CEO & Managing Director Company Secretary +61 8 6555 2950 +61 8 6555 2950 info@mgcpharma.co.uk info@mgcpharma.co.uk UK IR/PR Advisers UK Brokers IFC Advisory Oberon Capital Graham Herring / Tim Metcalfe / Aimee McCusker / Adam Pollock Zach Cohen +44 203 179 5300 +44 203 934 6630 aimeemccusker@oberon mgcpharma@investor-f |
Posted at 01/11/2023 07:21 by cal57 1 November 2023ASX Code: MXCLSE Code: MXC Fund RaisingMGC Secures US$7.9 Million In Firm Commitments for New MGC Pharmaceuticals Ltd (MGC Pharma, MGC or the Company) a European based pharmaceutical company specialising in the production and development of innovative medicines for unmet medical needs, is pleased to announce that following shareholder approval for a new share placement secured at the Company's General Meeting on 25th October 2023 (Placement), the Company confirms that it has received binding commitments from sophisticated and professional investors (Investors) to subscribe for US$8 million of new shares under the Placement, at an issue price of US$0.255 (A$0.40)1 per share (on a post-Consolidation basis).The issue of shares under the Placement is anticipated to occur in the next week, post completion of the 1:1000 consolidation of capital, as approved by shareholders at the same General Meeting on 25th October (Consolidation). Participants in the Placement will also receive one free attaching option for every two shares subscribed for and issued. The options will be exercisable at US$0.32 (A$0.50) (on a post-Consolidation basis), with a five-year term and will otherwise be issued on the terms and conditions set out in Schedule 1 of the Notice of Meeting dated 26 September 2023 (Options).Following the Placement, 31,000,000 fully paid ordinary shares and 15,500,000 Options will be issued with shareholder approval under Listing Rule 7.1 (obtained 25 October 2023).The US$7.9 million secured represents the minimum amount required to fund MGC Pharma's full business plan over the next 12-month period, that is focused on the IND applications of CimetrA and CannEpil in the USA .The Company currently intends to use the funds on the following basis2:? CannEpil® - initiation of phase II clinical trials (in Australia) and submission of the USA Investigational New Drug Application (Food and Drug Administration) - c.US$2.6m;? CimetrA® - completion of phase IIB dose finding study in Israel, and submission of the USA Investigational New Drug Application (Food and Drug Administration) c.US$2.4m;? Marketing and pharmaceutical conferences costs c.US$1.2m;? Working capital c.US$1.3m; and? Costs of placement including ASX, LSE costs and prospectus submission in the UK c.US$0.4mThe Company notes that the above use of funds is a statement of current intentions as of the date of this announcement. As with any budget, intervening events and new circumstances have the potential to affect the manner in which the funds are ultimately applied.The Investors were identified from within the existing network of the Company's Board and executive management through a bookbuild process, which involved seeking expressions of interest from unrelated professional investors, sophisticated investors and/or other investors that are exempt from the disclosure requirements in section 708 of the Corporations Act 2001 (Cth). Furthermore, the Company confirms that no fees will be paid to any party for managing the Placement.1 As approved by shareholders at the General Meeting held 25 October 2023, the issue price per share was equal to the volume weighted average |
Posted at 16/9/2023 08:03 by paulhopeful Heatseek77: Purchaseatthetop. SEAGREEN. Davethechef. Markliddiard. Papillon. 504. BSG. Coeun. Penstocks. Sirmark. Unionhall. Howdlep. Bad gateway. Festario. Goforgold1. Jailbird. 16 All same person ( pop up Pete ) deramping here, Ramping On Enet. Eisb. BENS CREEK. Iqai. Mos Boards, and more, good luck to all genuine investors. |
Posted at 12/7/2023 22:39 by goforgold1 Wow anyone go research on this bogus company lol giving MXC orders you be shocked . Is this not the company that placed a 24 million order lol years ago ha ha anyone been to Malta lately as well . .Total Scam how the hell they are allowed to trade is beyond me. Just a garden centre taking millions of pounds of private investors and pocketing the money go back and check had over 100 million yes 100 million from uk and Australia. Corruption at its best and LSE do nothing . |
Posted at 07/7/2023 06:38 by looneytune Dear Investor,Please find below the latest announcement from MGC Pharmaceuticals Ltd. (ASX:MXC). AMC Places Second Order of ArtemiC for US$1M Please click here to view the announcement. MGC Pharmaceuticals automatically sends price-sensitive ASX announcements to registered investors. Please visit our website to view all announcements. |
Posted at 01/6/2023 11:27 by looneytune It’s only an investor rolling his order! Ie.selling/buying in the one transaction. Can only do this limited times to save on paying for the initial purchase. Just delaying basically.This won’t affect the SP! |
Posted at 31/5/2023 13:40 by pierre oreilly Dear Investor,Please find below the latest announcement from MGC Pharmaceuticals Ltd. (LSE:MXC). First CannEpil® delivered to UK patients Please click here to view the announcement. |
Posted at 12/4/2023 07:58 by looneytune It’s all progress Heat. Just taking time, but logic says no high worth investors or indeed institutional investors are keen on losing money, hence their continued investment net in MGC. Don’t even know why you read the vitriol from the obvious low life’s on these boards. Onwards & upwards….the mugger11 Apr '23 - 17:17 - 4529 of 4534 (Filtered) 0 2 0 the mugger11 Apr '23 - 17:19 - 4530 of 4534 (Filtered) 0 1 0 the mugger11 Apr '23 - 19:39 - 4531 of 4534 (Filtered) 0 1 0 They even like their own nonsense - lol!!! |
Posted at 04/10/2022 07:07 by looneytune All positive!04/10/2022 7:00am UK Regulatory (RNS & others) TIDMMXC RNS Number : 6899B MGC Pharmaceuticals Limited 04 October 2022 MGC Pharmaceuticals Ltd. Appointment of UK Advisor, Hannam & Partners, and Company Update 4 October 2022 ASX, LSE: MXC MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to announce the formal appointment of UK capital markets advisor, Hannam & Partners, as financial and corporate advisors to the Company, with immediate effect ( ). Hannam & Partners are a highly regarded UK advisory firm with a long track record in UK capital markets, and more recently in the UK and EU cannabis sector. The Board believes that this appointment, along with delivery on the commercial contracts and production plans currently in place, will greatly enhance the Company's ability to maximise its enterprise value for all shareholders in the future. Appointment of new COO/Deputy CEO The Company advises that it has appointed Ms Yifat Steuer as the Company's new Chief Operating Officer/Deputy CEO, with Ms Steuer having been previously engaged as an advisor to the executive team during 2022. Ms Steuer has over 20 years of experience as an executive, working across a range of pharmaceutical companies including Johnson & Johnson and GlaxoSmithKline, as well experience working with SMEs and start-ups. Ms Steuer is a qualified Chartered Accountant and holds an MBA degree from Bayes Business School - University of London. Ms Steuer will work closely with CEO Roby Zomer to execute on MGC Pharma's business strategy, utilising her experience in in pharmaceuticals, manufacturing, logistics, medical technology and digital health. Chairman role change The Company also advises that Mr Brett Mitchell's role as Chairman of the Company's board of directors has transitioned from an executive to a non-executive position, to be more in line with corporate structuring of UK listed companies. Mr Mitchell will continue to provide corporate and capital markets advisory services to the Company through an existing consultancy agreement between MGC Pharma and Mr Mitchell's private consulting company, as disclosed in the Company's recent 2022 Annual Report. Investor Update - 11(th) October Following the release of our 2022 Annual Report, the company is pleased to announce that it will be providing a live presentation via the Investor Meet Company platform on 11th Oct 2022 at 11:00am BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can register with Investor Meet Company for free and add to meet MGC PHARMACEUTICALS LIMITED via: Investors who already follow MGC PHARMACEUTICALS LIMITED on the Investor Meet Company platform will automatically be invited. --Ends-- Authorised for release by the Chairman, for further information please contact: |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
